Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 12/30/2025

Guideline Recommendations for DSP‑Related Arrhythmogenic Cardiomyopathy

Initial Clinical Assessment

  • Refer all patients with suspected DSP‑related arrhythmogenic cardiomyopathy for immediate genetic counseling and testing because DSP pathogenic variants are linked to aggressive phenotypes and a high risk of sudden cardiac death even when systolic function is preserved. American Heart Association 1
  • Presence of conduction disease or ventricular arrhythmias should raise strong suspicion for arrhythmogenic cardiomyopathy and increased sudden‑death risk. American Heart Association 2

Diagnostic Imaging and Functional Evaluation

  • Transthoracic echocardiography is required to evaluate left‑ventricular size, systolic function, right‑ventricular morphology, and regional wall‑motion abnormalities. American Heart Association 1
  • Serial echocardiography every 1–2 years is recommended for first‑degree relatives who are genotype‑positive (or of unknown genotype) to monitor disease progression. American Heart Association 2
  • Cardiac magnetic resonance imaging is essential for DSP cardiomyopathy to delineate ventricular involvement, detect myocardial fibrosis with late gadolinium enhancement, and identify left‑ventricular non‑compaction patterns. American Heart Association 3

Genetic Testing Strategy

  • Test the most clearly affected family member (the proband) first to maximize diagnostic yield. American College of Medical Genetics (Class IIa) 4
  • DSP pathogenic variants constitute a major proportion of arrhythmogenic cardiomyopathy, especially with left‑ventricular predominance. American Heart Association 1
  • Pathogenic variants are identified in 25–40 % of dilated cardiomyopathy patients with a positive family history and in 10–30 % of those without a recognized family history. American Heart Association 2
  • Cascade genetic testing of at‑risk relatives for pathogenic or likely‑pathogenic DSP variants is a Class I recommendation. American College of Medical Genetics 4
  • First‑degree relatives should receive genetic screening and counseling to enable early detection and timely treatment aimed at reducing heart‑failure progression and sudden cardiac death. American Heart Association 1
  • Unless proven genotype‑negative, first‑degree relatives require periodic surveillance with ECG and echocardiography. American Heart Association 2
  • Genetic counseling before and after testing helps patients understand implications, including potential genetic discrimination. American Heart Association 1

Risk Stratification & Management

  • A personal history of cardiac arrest or sustained ventricular tachycardia qualifies as a high‑risk feature warranting ICD consideration. American Heart Association 3
  • A personal history of syncope that is suspected to be arrhythmic is also a high‑risk criterion for ICD implantation. American Heart Association 3
  • A family history of premature hypertrophic cardiomyopathy‑related sudden death, cardiac arrest, or sustained ventricular arrhythmias in close relatives is an additional high‑risk factor. American Heart Association 3
  • Genetic testing results should be incorporated into risk stratification and influence primary‑prevention ICD decisions. American Heart Association 1
  • Primary‑prevention ICD placement in asymptomatic carriers of malignant DSP pathogenic variants improves long‑term clinical outcomes. American College of Medical Genetics (Class IIa) 4
  • Exercise restriction is advised for individuals with desmosomal (including DSP) variants, mirroring recommendations for hypertrophic cardiomyopathy. American Heart Association 2
  • Decisions about participation in competitive sports should consider family history of sudden cardiac death, the type of sport, and the patient’s/ family’s risk tolerance. American Heart Association 3
  • When ventricular dysfunction develops, guideline‑directed medical therapy for heart failure should be initiated promptly. American Heart Association 1

Ongoing Surveillance

  • Perform a comprehensive, systematic, non‑invasive sudden‑cardiac‑death risk assessment at initial evaluation and repeat every 1–2 years. American Heart Association 3
  • Continue serial echocardiography and ECG for genotype‑positive family members to detect phenotypic evolution. American Heart Association 2

All facts are derived from peer‑reviewed guideline sources; citation IDs correspond to the original references.

Evidence‑Based Recommendations for Desmoplakin (DSP) Cardiomyopathy

Genetic Risk and Phenotypic Expression

  • Pathogenic DSP variants are associated with an aggressive arrhythmogenic phenotype and a high risk of sudden cardiac death even when left‑ventricular systolic function is preserved. European Society of Cardiology guidance supports early genetic evaluation in these patients. 5
  • In individuals initially diagnosed with dilated cardiomyopathy, identification of a desmosomal (DSP) variant predicts a worse arrhythmic course and an increased risk of sudden death that is independent of left‑ventricular ejection fraction. European Society of Cardiology data underline the prognostic value of genetic testing. 6

Implantable Cardioverter‑Defibrillator (ICD) and Arrhythmia Management

  • A left‑ventricular ejection fraction < 35 % after at least three months of optimal heart‑failure therapy qualifies as a high‑risk feature warranting primary‑prevention ICD consideration. American Heart Association criteria incorporate this threshold. 7
  • Prophylactic ICD decisions should not rely solely on ejection‑fraction metrics because DSP‑related desmosomal mutations can precipitate life‑threatening ventricular arrhythmias despite preserved systolic function. American Heart Association emphasizes a comprehensive risk assessment. 8
  • Delaying ICD evaluation based only on a preserved ejection fraction is discouraged; arrhythmic risk in DSP cardiomyopathy remains high irrespective of left‑ventricular performance. European Society of Cardiology recommendations highlight this pitfall. 5

Exercise Restriction

  • Mandatory exercise restriction is advised for all carriers of desmosomal (including DSP) variants, mirroring recommendations for hypertrophic cardiomyopathy. American Heart Association endorses this precaution. 7
  • Endurance and high‑intensity exercise are linked to increased penetrance and incident arrhythmias among family members with desmosomal variants; therefore, such activities should be avoided to limit phenotypic expression. European Society of Cardiology evidence supports this restriction. 5

Surveillance and Family Screening

  • Ambulatory electrocardiographic monitoring (e.g., Holter) is reasonable every 1–3 years, with interval selection based on patient age, left‑ventricular ejection fraction, and overall clinical assessment. American Heart Association surveillance guidelines recommend this schedule. 9
  • After a proband is diagnosed with arrhythmogenic cardiomyopathy, first‑degree relatives aged ≥ 10 years should undergo baseline cardiovascular screening—including 12‑lead ECG, ambulatory ECG, and cardiac imaging—to enable early detection. European Society of Cardiology screening protocol applies. 6

Dermatologic Manifestations

  • DSP mutations may present with woolly hair, a cutaneous sign that can aid in phenotypic recognition. European Society of Cardiology notes this association. 5
  • Palmoplantar keratoderma is another cutaneous feature linked to DSP pathogenic variants, warranting dermatologic evaluation when present. European Society of Cardiology includes this observation. 5

Clinical Pitfalls to Avoid

  • Do not rely exclusively on traditional arrhythmogenic right‑ventricular cardiomyopathy Task Force criteria for diagnosis, as they have limited sensitivity (≈ 73 %) for left‑dominant DSP disease and may miss up to 23 % of patients with sustained ventricular arrhythmias. European Society of Cardiology highlights this limitation. 8

REFERENCES